Prelude Therapeutics Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About PRLD
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Find out what a historical investment in Prelude Therapeutics Inc would be worth today using our PRLD stock calculator.
$44.05M
-
0.00%
0
$0.85
$0.78
$0.00
$6.80
$0.61
Ready to start your investing journey with Stake?
Open an accountPRLD FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in PRLD
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in PRLD
on Stake
Buy PRLD from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of PRLD from only US$10 with fractional shares
